ERBB2 and ovarian carcinoma: In conclusion, this study demonstrated that the combination of samfenet, a biosimilar compound of trastuzumab, and NK cell therapy showed remarkable antitumor efficacy in a preclinical model of HER2-overexpressing ovarian cancer through the ADCC effect.